Suppr超能文献

当代应用于隐静脉移植介入术的栓塞保护装置。

Contemporary Use of Embolic Protection Devices During Saphenous Vein Graft Intervention.

机构信息

Department of Medicine, Division of Cardiology, Rocky Mountain Regional VA Medical Center, Aurora, CO (J.A.V., T.J.G., E.J.A., S.W.W.).

University of Colorado School of Medicine, Aurora (J.A.V., E.J.A., S.W.W.).

出版信息

Circ Cardiovasc Interv. 2019 May;12(5):e007636. doi: 10.1161/CIRCINTERVENTIONS.118.007636.

Abstract

BACKGROUND

Guidelines recommend use of embolic protection devices during percutaneous coronary intervention of saphenous vein grafts, but the use of these devices in contemporary practice is unclear. We thus sought to evaluate the patient characteristics and clinical outcomes associated with embolic protection device use during contemporary saphenous vein graft percutaneous coronary intervention.

METHODS AND RESULTS

We identified patients undergoing isolated saphenous vein graft percutaneous coronary intervention in the Veterans Affairs Healthcare System from January 2008 to June 2017. Patient and procedural characteristics associated with embolic protection device use were assessed, as well as unmeasured site variation. A propensity-matched cohort was constructed to compare outcomes at 30 days, including unsuccessful intervention, periprocedural myocardial infarction, and death. We identified 7266 vein graft interventions, and embolic protection was used in 37.9% of cases, with a significant decline over time ( P=0.001) that was most pronounced from 2014 to 2017 ( P<0.001). There was significant institutional variation in the use of embolic protection, with a 15.50 (95% credible interval, 9.21-29.71)-fold difference in odds of device use by changing facilities independent of patient or procedural factors. Use of embolic protection was associated with reduced risk of unsuccessful intervention (odds ratio, 0.27; 95% credible interval, 0.17-0.42) and 30-day mortality (odds ratio, 0.56; 95% credible interval, 0.36-0.87).

CONCLUSIONS

Use of embolic protection is decreasing with time and occurs in less than half of vein graft interventions. There is significant site variation in the use of embolic protection independent of patient characteristics, suggesting opportunities for the development of uniform practices to improve outcomes among those undergoing saphenous vein graft percutaneous coronary intervention.

摘要

背景

指南建议在经皮冠状动脉介入治疗(PCI)中使用栓塞保护装置,但这些装置在当代实践中的使用情况尚不清楚。因此,我们旨在评估在当代大隐静脉桥 PCI 中使用栓塞保护装置与患者特征和临床结局的关系。

方法和结果

我们从 2008 年 1 月至 2017 年 6 月期间在退伍军人事务医疗保健系统中识别出接受孤立大隐静脉桥 PCI 的患者。评估了与栓塞保护装置使用相关的患者和手术特征,以及未测量的站点差异。构建倾向匹配队列以比较 30 天的结局,包括干预不成功、围手术期心肌梗死和死亡。我们确定了 7266 例静脉桥干预,其中 37.9%的患者使用了栓塞保护装置,且使用比例随时间呈显著下降趋势(P=0.001),从 2014 年至 2017 年最为明显(P<0.001)。栓塞保护装置的使用存在显著的机构差异,改变机构独立于患者或手术因素,装置使用的可能性差异为 15.50 倍(95%可信区间,9.21-29.71)。使用栓塞保护装置与降低干预不成功的风险(比值比,0.27;95%可信区间,0.17-0.42)和 30 天死亡率(比值比,0.56;95%可信区间,0.36-0.87)相关。

结论

栓塞保护装置的使用随时间减少,不到一半的静脉桥干预使用栓塞保护装置。栓塞保护装置的使用存在显著的站点差异,独立于患者特征,表明有机会制定统一的实践,以改善接受大隐静脉桥 PCI 治疗的患者的结局。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验